| Literature DB >> 33392382 |
David Bissig1, Jeffrey Kaye2, Deniz Erten-Lyons3.
Abstract
BACKGROUND: Cognitive screening is limited by clinician time and variability in administration and scoring. We therefore developed Self-Administered Tasks Uncovering Risk of Neurodegeneration (SATURN), a free, public-domain, self-administered, and automatically scored cognitive screening test, and validated it on inexpensive (<$100) computer tablets.Entities:
Keywords: Alzheimer's disease; cognitive screening; computer‐based test; dementia screening; psychometrics; self‐administered cognitive test
Year: 2020 PMID: 33392382 PMCID: PMC7771179 DOI: 10.1002/trc2.12116
Source DB: PubMed Journal: Alzheimers Dement (N Y) ISSN: 2352-8737
Summary of computerized self‐administered cognitive screening tests
| Cognitive Domains Assessed | Study Diagnoses | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Name | Memory | Orientation | Visuospatial | Executive | Calculation | Sustained Attention | Expressive Language | Time (min) | Accommodates Hearing Loss | Participants (n) Age ≥ 50 yr | MCI | Dementia | Free to Use | Reference |
| ACAD | + | + | 20 | ++ | 32 |
| ||||||||
| BCSD | + | + | + | + | 15 | ++ | 101 | + | + |
| ||||
| CAMCI | + | + | + | 30 | + | 263 | + | ‐ |
| |||||
| CANS‐MCI | + | + | + | + | >30 | 310 | ‐ |
| ||||||
| 50 | 97 | + | + | ‐ |
| |||||||||
| CANTAB PAL | + | + | 58 | + | + | ‐ |
| |||||||
| ClockMe | + | + | <2 | + | 20 |
| ||||||||
| 40 |
| |||||||||||||
| CNS Vital Signs | + | + | + | 30 | ++ | 347 | + | + | ‐ |
| ||||
| Cogstate Brief Battery | + | + | 20 | ++ | 1273 | ‐ |
| |||||||
| 765 | + | + |
| |||||||||||
| C‐TOC | + | + | + | + | + | 45 | + | 76 | + | + |
| |||
| CUPDE | + | + | + | + | 30 |
| ||||||||
| CUPDE2 | + | + | + | + | ? | ? | 21 |
| ||||||
| DETECT | + | + | + | 10 | + | 405 | + | + | ‐ |
| ||||
| Dtmt | + | + | + | 81 | + |
| ||||||||
| eCTT | + | + | ++ | 21 |
| |||||||||
| eSAGE | + | + | + | + | + | + | 18 | ++ | 66 | + | + | ‐ |
| |
| GrayMatters | + | + | 20 | + | 251 | + | ‐ |
| ||||||
| IVR | + | + | + | 10 | 61 | ‐ |
| |||||||
| MicroCog/ACS | + | + | + | + | + | >30 | 102 | + | ‐ |
| ||||
| Revere | + | 153 | + | ‐ |
| |||||||||
Abbreviations: ACAD, Automatic Cognitive Assessment Delivery; ACS, Assessment of Cognitive Skills; BCSD, Brief Computerized Self‐screen for Dementia; CADi, Cognitive Assessment for Dementia iPad version; CADi2, Cognitive Assessment for Dementia iPad version revised; CAMCI, Computerized Assessment of Mild Cognitive Impairment; CANS‐MCI, Computer‐Administered Neuropsychological Screen for Mild Cognitive Impairment; CANTAB PAL, Cambridge Neuropsychological Test Automated Battery Paired Associate Learning; C‐TOC, Cognitive Testing on Computer; CUPDE, Cambridge University Pen to Digital Equivalence; CUPDE2, Cambridge University Pen to Digital Equivalence revised; DETECT, Display Enhanced Testing for Cognitive impairment and Traumatic brain injury; dTMT, digital version of the Trails Making Task parts A and B; eCTT, electronic version of the Color Trails Test; eSAGE, electronic version of the Self‐Administered Gerocognitive Examination; IVR, Interactive Voice Response; MCS, Mobile Cognitive Screening; SATURN, Self‐Administered Tasks Uncovering Risk of Neurodegeneration; TPDAS, Touch Panel‐type Dementia Assessment Scale; TPST, Touch‐Panel Computer Assisted Screening Tool.
We omit studies that only tested those age <50 years, studies without an English‐language publication (eg, the CogVal‐Senior listed in a recent review ), and studies where a skilled operator participated in testing, as when training a participant (eg, task demonstration), , reinforcing instructions, or similar. , For brevity, only one or two publications are selected for each test. The total number of participants, and inclusion (or not) of patients with dementia and mild cognitive impairment (MCI), was extracted from those specific publications. The cumulative literature experience with some tests, like MicroCog, is more extensive than listed here.
Includes tasks that better challenge and report on participant attention than the “Simple Attention” items in SATURN. Examples include backward digit span and working memory tasks. ,
Where a range of times was provided, we tabled the larger value to reflect expectations for cognitively impaired participants, who are generally slower than age‐matched controls. The tabled value for SATURN is above the median time for participants with a clinical dementia rating scale global score of 1.0 (Table S1). Except for Revere (for which time is difficult to report due to a 20 minutes delay built into their test procedure), values are left blank if insufficient information was provided to judge test duration.
++ indicates that all testing was done without an audio device (speakers or headphones). + indicates that the study used some audio, but trivial protocol changes might make it audio‐free (eg, written instructions accompanied by a recording of those instructions read aloud, for redundancy). Outside of those categories, some tests with auditory stimuli nevertheless carry many audio‐free items, and truncated versions may be useful in the hearing impaired.
++ indicates public domain. – indicates that the test has been commercialized, including cases using automatic speech recognition technology , and cases where we are unsure if the company is still active.
FIGURE 1Relationship between scores on the Montreal Cognitive Assessment (MoCA) and Self‐Administered Tasks Uncovering Risk of Neurodegeneration (SATURN), and their association with clinical status, quantified by the Clinical Dementia Rating (CDR) scale. (A) SATURN and MoCA scores are strongly correlated. Scorable participant data from all three versions of SATURN (n = 75) are shown as translucent circles, so that overlapping points appear darker. The ×s denote data from “unscorable” participants and are staggered slightly where they would otherwise overlap. (These conventions are carried through the plots in B, although, by design, the beeswarm plots for CDRglobal have no overlapping points.) The best‐fit line for the correlation among scorable participants is pictured (solid line; MoCA = 0.786 × SATURN + 5.663; r = 0.90; P < .00001) along with its 95% confidence interval (dashed lines). The 50% prediction interval (not shown) is roughly 1.5 points above and below the regression line throughout. Thus at least half of those with a SATURN score of 28 will score between a 26 and 29 on the MoCA. (B) The relationship between CDRglobal scores and SATURN scores (top) and MoCA scores (bottom) are detailed by beeswarm plots overlaid on box‐and‐whisker plots. Both SATURN and MoCA were strongly associated with CDRglobal score (analysis of variance [ANOVA]; F[3,56] = 46.8 and F[3,56] = 75.8 respectively, both P < .00001). Harmonizing this plot with Table 1, we note that those 10 participants with a CDRglobal = 0.5 had clinical diagnoses of either mild cognitive impairment (n = 3) or mild dementia (n = 7) per American Academy of Neurology guidelines. To the right of the figure, those with nonzero CDRglobal scores are re‐plotted according to their specific CDRSOB scores. Since CDRSOB = 0 for all those with CDRglobal = 0.0, their data are not re‐plotted into the CDRSOB plot. The relationship between CDRSOB and both SATURN and MoCA was robust (linear regression; r = −0.83 and r = −0.86 respectively; P < .00001). (C) Receiver‐operating characteristic (ROC) curves detail the ability of both MoCA (gray) and SATURN (black) to detect cognitive impairment. On the left, cognitive impairment is defined as CDRglobal >0. Based on these data, it is optimal to label one cognitively impaired if one's score is <24 on SATURN (sensitivity 82%, specificity 92%) or <26 on the MoCA (sensitivity 91%, specificity 82%). Area under the curve (AUC) was similar for each test (P > .19; 0.95 for MoCA [95% CI 0.89 to 1.0], versus 0.90 for SATURN [95% CI 0.82 to 0.95]). For illustrative purposes, points are overlaid on the ROC curves at cutoffs of <22, <24, <26, and <28 for both tests. On the right, cognitive impairment is defined as CDRglobal >0.5. Based on these data, it is optimal to label one cognitively impaired if one's score is <21 on SATURN (sensitivity 92%, specificity 88%) or <23 on the MoCA (sensitivity 92%, specificity 88%). AUC was similar for each test (P = .8; 0.94 for MoCA [95% CI 0.85 to 1.0], versus 0.95 for SATURN [95% CI 0.87 to 1.0]). Points are overlaid on the ROC curves cutoffs of <19, <21, <23, and <25 for both tests
Demographics, mean performance, and survey results of “scorable” participants
| Age | Sex | Education | Test preference (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Participant source | n | (years) | (%women) | (years) | MoCA | SATURN | %Report SATURN “Easy to Use” | MoCA | No Pref. | SATURN |
| Study partner | 37 | 65.5 ± 9.2 | 59 | 16.3 ± 2.5 | 27.0 ± 1.8 | 27.1 ± 2.6 | 97 | 8 | 30 | 62 |
| Dementia clinic | 24 | 71.5 ± 10.3 | 46 | 15.5 ± 3.0 | 19.1 ± 6.1 | 17.5 ± 6.4 | 63 | 42 | 38 | 21 |
| Not Demented | 4 | 74.3 ± 6.1 | 50 | 15.8 ± 1.6 | 24.8 ± 3.8 | 24.3 ± 4.1 | 75 | 25 | 75 | 0 |
| Alzheimer's | 13 | 68.5 ± 11.3 | 46 | 16.4 ± 2.6 | 18.5 ± 5.6 | 16.4 ± 6.0 | 54 | 54 | 31 | 15 |
| Other Dementia | 7 | 75.6 ± 9.2 | 29 | 13.7 ± 3.8 | 16.9 ± 6.6 | 15.7 ± 6.2 | 71 | 29 | 29 | 43 |
| Other Clinic | 14 | 65.9 ± 7.6 | 36 | 15.5 ± 3.6 | 24.8 ± 3.3 | 23.6 ± 3.6 | 79 | 21 | 29 | 50 |
| Multiple Sclerosis | 2 | 62.5 ± 7.8 | 100 | 15.0 ± 1.4 | 28.0 ± 1.4 | 26.5 ± 2.1 | 100 | 50 | ‐ | 50 |
| Essential Tremor | 1 | 66 | 100 | 14 | 27 | 25 | 100 | ‐ | ‐ | 100 |
| Parkinson | 11 | 66.5 ± 8.2 | 18 | 15.7 ± 4.0 | 24.0 ± 3.3 | 23.0 ± 3.7 | 73 | 18 | 36 | 45 |
Shaded rows break down patients from each clinic into more specific diagnoses. Other than group sizes (n), data are presented as percentages or as mean ± standard deviation. The MoCA and SATURN are scored out of 30 points.
Includes three patients with mild cognitive impairment, and a cognitively normal carrier of an apolipoprotein E (APOE) ε4 allele
The clinical diagnosis was Alzheimer's disease for all but one, for whom cerebrospinal fluid implicated Alzheimer's disease as the cause of corticobasal syndrome
Includes one case of Lewy body dementia, three cases predominantly or exclusively caused by cerebrovascular disease, and another three of mixed or uncertain cause. To simplify presentation, this row includes a patient with known dementia who was seen in general neurology clinic for peripheral neuropathy on the day of testing (and therefore not assigned CDR scores).